Full Breakdown
FDA Authorizes Juul2 with Optional Age-Verification Feature
8/29/2026, 8:56:43 PM
Core Event
On August 28 2026, the U.S. Food and Drug Administration (FDA) granted Juul Labs permission to market an updated e-cigarette, Juul2, and two flavored pod variants—tobacco and menthol—each containing 18 mg/mL nicotine (?1.5 %–1.6 %). Juul2 includes an optional age-verification system that unlocks the device only after users confirm their age through an online app.
Background & Context
Juul’s original products once dominated the U.S. market but faced lawsuits over teen use, leading to a roughly $3 billion settlement and workforce reductions. After the FDA’s 2022 marketing denial orders were rescinded in 2024, five original Juul products were authorized in July 2025. The Juul2 platform, first launched in the U.K. in 2021, is the company’s first new U.S. device in more than a decade.
Timeline
- June 2022 – FDA issues marketing denial orders for original Juul.
- June 2024 – Denial orders placed under administrative stay and rescinded.
- July 2025 – FDA authorizes five original Juul products.
- August 28 2026 – FDA authorizes Juul2 and tobacco- and menthol-flavored pods.
- August 29 2026 – 2Firsts reports on the decision.
Data & Statistics
- FDA cited adult-smoker switching rates of 28.4 %–49.3 % for the menthol pod and 19.9 %–34.6 % for the tobacco pod after six weeks of exclusive use.
- Company studies indicated 20 %–50 % of adult smokers who used Juul products stopped smoking entirely within six weeks.
- The authorization brings the total number of FDA-authorized e-cigarette products to 48.
Official Statements & Responses
- The FDA stressed the decision is not an approval or endorsement and warned non-smokers to avoid e-cigarettes. It noted that switching to Juul2 reduces exposure to carcinogens found in combustible cigarettes.
- FDA officials said the menthol product’s benefit to adult smokers outweighed youth-appeal risks, without detailing the role of age-verification technology.
- Bret Koplow, Acting Director of the Center for Tobacco Products, reported a ?70 % reduction in the PMTA backlog during 2025 and streamlined review stages.
Why It Matters / Impact
The authorization signals Juul’s shift from litigation to a commercial relaunch aimed at adult smokers. By pairing its delivery platform with optional age-verification, Juul seeks to rebuild regulatory trust and regain market share lost to rivals such as Vuse. Public-health officials view the adult-switching data as a potential harm-reduction benefit, while the agency continues to monitor youth-access risks. The FDA’s broader effort to accelerate PMTA reviews could expand the pool of legally marketed alternatives, affecting competition and consumer choice in the U.S. vaping market.
What’s Next
The FDA will apply efficiency measures from its nicotine-pouch pilot to other product reviews and maintain enforcement priorities for unauthorized e-cigarettes and nicotine pouches. How age-verification technology will influence future authorizations remains unspecified.
